Respiratory Disease
Conditions
Brief summary
This is a phase 4, randomized, double-blind, multicenter clinical trial to evaluate the efficacy and safety of YMC026 in respiratory disease patients with cough and sputum as the main symptoms
Detailed description
The study has planned 4 visits during 2 weeks period (1 week of screening period, 1 week of treatment period). All subjects who agree to participate in the study and voluntarily give written informed consent are assessed by inclusion and exclusion criteria at the screening visit. After the screening period, the final eligibility of the subjects will be assessed at the randomization visit. Subjects who are determined to be appropriate for this study will be allocated to experimental group(YMC026) or control group(placebo) randomly in a 1:1 ratio. Subject will be administered the investigational product daily for 6 days. The safety for the subjects will be assessed at Day 3 and Day 6 visit, and the efficacy evaluation will be assessed at Day 6 visit.
Interventions
DRUGYMC026
YMC026 20mL TID
DRUGPlacebo
Placebo 20mL TID
Sponsors
Yuhan Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
15 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
1. Both gender, 15 years ≤ age \< 75 years 2. Patients with BSS(Bronchitis Severity Score) ≥ 5point at screening visit and randomization visit 3. Written consent voluntarily to participate in this clinical trial
Exclusion criteria
1. Patients with severe respiratory disease 2. Patients with severe pulmonary disease 3. Patients who has history for drug hypersensitivity or allergic reaction in component of investigational product or similar drug 4. Patients with pregnant and/or have breast feeding 5. Patients who were treated with monoamine oxidase inhibitor, antihistamines, anti-viral drugs and glucocorticoids within 2 weeks prior to administration of investigational product 6. Patients who were treated with β2-agonist and anticholinergic drug within 1 weeks prior to administration of investigational product 7. Patients who were treated with secretolytics, mucolytics and bronchodilators within 1 day prior to administration of investigational product 8. Patients who are participating in another trial within 30 days prior to screening visit 9. Patients who investigators determines not appropriate to take part in this clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline BSS at Day 6 | Baseline(Day 0), Day 6 | Bronchitis Severity Score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline BCSS at Day 6 | Baseline(Day 0), Day 6 | Breathlessness, Cough, and Sputum Scale |
| Patients´ evaluation of symptoms of cough and sputum on patient's diary | Day 6 | — |
Countries
South Korea
Outcome results
None listed